Nanobodies Are Potential Therapeutic Agents for the Ebola Virus Infection

Ebola fever is an acute, highly contagious viral disease with a mortality rate that can reach 90%. There are currently no licensed therapeutic agents specific to Ebola in the world. Monoclonal antibodies (MAbs) with viral-neutralizing activity and high specificity to the Ebola virus glycoprotein (EBOV GP) are considered as highly effective potential antiviral drugs. Over the past decade, nanobodies (single-domain antibodies, non-canonical camelid antibodies) have found wide use in the diagnosis and treatment of various infectious and non-infectious diseases. In this study, a panel of nanobodies specifically binding to EBOV GP was obtained using recombinant human adenovirus 5, expressing GP (Ad5-GP) for alpaca (Vicugna pacos) immunization, for the first time. Based on specific activity assay results, affinity constants, and the virus-neutralizing activity against the recombinant vesicular stomatitis virus pseudotyped with EBOV GP (rVSV-GP), the most promising clone (aEv6) was selected. The aEv6 clone was then modified with the human IgG1 Fc fragment to improve its pharmacokinetic and immunologic properties. To assess the protective activity of the chimeric molecule aEv6–Fc, a lethal model of murine rVSV-GP infection was developed by using immunosuppression. The results obtained in lethal model mice have demonstrated the protective effect of aEv6–Fc. Thus, the nanobody and its modified derivative obtained in this study have shown potential protective value against Ebola virus.

[1]  A. Gintsburg,et al.  Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection. , 2019, Antiviral research.

[2]  X. Qiu,et al.  The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development , 2019, Viruses.

[3]  A. N. Noskov,et al.  Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice , 2019, Toxins.

[4]  H. Feldmann,et al.  Therapeutic strategies to target the Ebola virus life cycle , 2019, Nature Reviews Microbiology.

[5]  N. Butler,et al.  TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis , 2019, PLoS neglected tropical diseases.

[6]  Iebe Rossey,et al.  Single-Domain Antibodies and Their Formatting to Combat Viral Infections , 2018, Antibodies.

[7]  X. Qiu,et al.  Animal models for filovirus infections , 2018, Zoological research.

[8]  Shibo Jiang,et al.  Single-Domain Antibodies As Therapeutics against Human Viral Diseases , 2017, Front. Immunol..

[9]  E. Goldman,et al.  Selection, characterization, and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein , 2017, Microbial Cell Factories.

[10]  R. Webby,et al.  A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment , 2017, Antiviral research.

[11]  L. Sherwood,et al.  Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging , 2017, Front. Immunol..

[12]  A. Gintsburg,et al.  Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia , 2017, Human vaccines & immunotherapeutics.

[13]  S. Agnandji,et al.  Monoclonal antibodies for the treatment of Ebola virus disease , 2016, Expert opinion on investigational drugs.

[14]  J. Mascola,et al.  Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody , 2016, Science.

[15]  A. N. Noskov,et al.  Protective Immune Response against Bacillus anthracis Induced by Intranasal Introduction of a Recombinant Adenovirus Expressing the Protective Antigen Fused to the Fc-fragment of IgG2a , 2014, Acta naturae.

[16]  D. Dobson,et al.  PLOS Neglected Tropical Diseases , 2014 .

[17]  E. Riedmann.  Human Vaccines & Immunotherapeutics , 2013, Human Vaccines & Immunotherapeutics.

[18]  L. Sherwood,et al.  Ebolavirus Nucleoprotein C-Termini Potently Attract Single Domain Antibodies Enabling Monoclonal Affinity Reagent Sandwich Assay (MARSA) Formulation , 2013, PloS one.

[19]  X. Qiu,et al.  Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies , 2012, Science Translational Medicine.

[20]  X. Qiu,et al.  Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection , 2012, PLoS neglected tropical diseases.

[21]  M. Harmsen,et al.  Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. , 2005, Vaccine.

[22]  Serge Muyldermans,et al.  Efficient tumor targeting by single‐domain antibody fragments of camels , 2002, International journal of cancer.